| Literature DB >> 34576238 |
América Vera-Montecinos1, Ricard Rodríguez-Mias2, Karina S MacDowell3,4, Borja García-Bueno3,4, Álvaro G Bris3,4, Javier R Caso3,4, Judit Villén2, Belén Ramos1,4,5,6,7.
Abstract
Despite the growing importance of the cerebellum as a region highly vulnerable to accumulating molecular errors in schizophrenia, limited information is available regarding altered molecular networks with potential therapeutic targets. To identify altered networks, we conducted one-shot liquid chromatography-tandem mass spectrometry in postmortem cerebellar cortex in schizophrenia and healthy individuals followed by bioinformatic analysis (PXD024937 identifier in ProteomeXchange repository). A total of 108 up-regulated proteins were enriched in stress-related proteins, half of which were also enriched in axonal cytoskeletal organization and vesicle-mediated transport. A total of 142 down-regulated proteins showed an enrichment in proteins involved in mitochondrial disease, most of which were also enriched in energy-related biological functions. Network analysis identified a mixed module of mainly axonal-related pathways for up-regulated proteins with a high number of interactions for stress-related proteins. Energy metabolism and neutrophil degranulation modules were found for down-regulated proteins. Further, two double-hit postnatal stress murine models based on maternal deprivation combined with social isolation or chronic restraint stress were used to investigate the most robust candidates of generated networks. CLASP1 from the axonal module in the model of maternal deprivation was combined with social isolation, while YWHAZ was not altered in either model. METTL7A from the degranulation pathway was reduced in both models and was identified as altered also in previous gene expression studies, while NDUFB9 from the energy network was reduced only in the model of maternal deprivation combined with social isolation. This work provides altered stress- and mitochondrial disease-related proteins involved in energy, immune and axonal networks in the cerebellum in schizophrenia as possible novel targets for therapeutic interventions and suggests that METTL7A is a possible relevant altered stress-related protein in this context.Entities:
Keywords: networks; pathways; postmortem brain; proteomics; schizophrenia
Mesh:
Substances:
Year: 2021 PMID: 34576238 PMCID: PMC8469990 DOI: 10.3390/ijms221810076
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Quantitative proteomic analysis in the cerebellum in chronic schizophrenia. (A) Experimental design for proteomic analysis to identify altered pathways in schizophrenia. Protein lysates from the postmortem cerebellum of control C (n = 14) and chronic schizophrenia (SZ) patients (n = 12) were processed as described. The peptides were separated and analyzed by liquid chromatography (LC) coupled with tandem mass spectrometry. The relative fold change of peptides was integrated into protein changes. The individual protein signatures for each case and control were used to generate hierarchical clusters. The prioritization of altered proteins (P1-Pn represents generic proteins) in SZ was obtained by comparing protein fold changes between control and SZ groups (significant proteins adjusted using an FDR of 0.1). We performed two analyses for these altered proteins in SZ: (i) unsupervised hierarchical clustering analysis generated from quantified proteins in 12 SZ and 14 healthy control samples of postmortem cerebellum; and (ii) generation of networks from significantly enriched pathways by protein–protein interaction. These analyses were performed using Perseus and String, respectively. (B) A correlation matrix for 1474 quantified proteins across sample pairs. (C) Unsupervised hierarchical clustering analysis was obtained with matrix processing according to the Euclidean distance and z-score aggregation method. Protein profiles were generated from 1474 quantified proteins in 12 SZ and 14 healthy control samples of postmortem cerebellum and were clustered according to the z-score and displayed as a heat map. Green color clusters represent under-expressed proteins. Red color clusters represent overexpressed proteins. (D) Volcano plot of the −log10 q-value (adjusted p-value; FDR (≤0.1)) versus the log2 fold change in the cerebellum in SZ relative to healthy control. SZ, schizophrenia; C, control. Up-regulated and down-regulated significant proteins are represented in red and green, respectively. The grey line shows the FDR threshold. (E) Venn diagram showing overlap between proteins previously reported in SZ through gene expression analysis obtained from SZDB (human cerebellum and iPSC) and our proteomic study in cerebellum.
Figure 2Enrichment analyses from proteome cerebellum in chronic schizophrenia. The bubble chart showing enriched disease categories (A), biological processes (B) and pathways (C) for 142 down-regulated proteins and 108 up-regulated proteins in SZ. (A) The enriched categories for the down-regulated proteins were mitochondrial diseases (PA447172) and mental disorders (PA447208), and for the up-regulated proteins they were stress (PA445752), drug interactions with drugs (PA165108622) and neurodegenerative diseases (PA446858). (B) Non-redundant enriched biological process categories for down-regulated proteins in SZ were generation of precursor metabolites and energy (GO: 0006091), mitochondrial respiratory chain complex assembly (GO: 0033108), nucleoside triphosphate metabolic process (GO: 0009141) and glycosyl compound metabolic process (GO: 1901657). For up-regulated proteins, the enriched biological functions were regulation of cytoskeleton organization (GO: 0051493), organelle localization (GO: 0051640), axon development (GO: 0061564), establishment or maintenance of cell polarity (GO: 0007163), regulation of cell morphogenesis (GO: 0022604), regulation of apoptotic signaling pathway (GO: 2001233), regulation of anatomical structure size (GO: 0090066) and microtubule-based movement (GO: 0007018). (C) The enriched pathway categories in SZ for the down-regulated proteins were citric acid (TCA) cycle/respiratory electron transport (R-HSA-1428517) and neutrophil degranulation (R-HSA-6798695). The enriched pathways for the up-regulated proteins were vesicle-mediated transport (R-HSA-5653656), apoptosis (R-HSA-109581), signaling mediated by Rho GTPase effectors (R-HSA-195258), signaling by Rho GTPases (R-HSA-194315), axon guidance (R-HSA-422475) and cell cycle (R-HSA-1640170). The X-axes show the mean of normalized LFQ intensity in SZ relative to control group for all the proteins that belonged to each category. The Y-axes show the –log10 enrichment p-value. The bubble size is directly proportional to the number of proteins represented in each enriched category of diseases, biological processes or pathways. Red color represents up-regulated proteins. Green color represents down-regulated proteins. SZ, schizophrenia; C, control.
Non-redundant categories of disease, gene ontology and pathways among 250 altered proteins filtered by multiple comparison, FDR = 0.1.
| CLASSIFICATION | CATEGORY | PROTEIN OVERLAP IN CATEGORY | Total Number | Observed Number | E | FDR | |
|---|---|---|---|---|---|---|---|
| Up-regulated proteins | |||||||
|
| Stress | SYCRIP; COMT; TXN2; | 592 | 13 | 2.20 | 2.30 × 10–7 | 6.02 × 10–4 |
| Drug interaction with drug | HSPA9; LRP1 b; ARRB1 b; PPIA; MAPK1; DIABLO; TPT1; YWHAB; YWHAZ | 423 | 9 | 1.57 | 2.56 × 10–5 | 3.36 × 10–2 | |
| Neurodegenerative | DCTN1; HSPA9; LRP1 b; MAP1B; RTN1 b; SNCG; SNRPD1; SOD1 b; UCHL1 | 473 | 9 | 1.76 | 6.11 × 10–5 | 5.33 × 10–2 | |
|
| Regulation of cytoskeleton organization | ARPC2 b; ARPC1A b; DCTN1; CLASP1; ARHGDIA; LRP1 b; PAFAH1B1 a; | 414 | 12 | 2.08 | 9.29 × 10–7 | 7.08 × 10–4 |
| Organelle localization | DCTN2 b; DCTN1; CLASP1; MAP1B; | 495 | 12 | 2.49 | 5.91 × 10–6 | 2.25 × 10–3 | |
| Axon development | RAB10; RAB21 a; ARHGDIA; MAP1B; NRCAM; PAFAH1B1 a; PITPNA b; | 452 | 11 | 2.27 | 1.46 × 10–5 | 3.71 × 10–5 | |
| Establishment or | RAB10; CLASP1; MAP1B; | 168 | 7 | 0.85 | 2.10 × 10–5 | 4.0 × 10–3 | |
| Regulation of cell | ARPC2 b; RAB21 a; ARHGDIA; MAP1B; | 433 | 10 | 2.18 | 5.78 × 10–5 | 6.29 × 10–3 | |
| Regulation of apoptotic | 369 | 9 | 1.86 | 9.24 × 10–5 | 8.80 × 10–3 | ||
| Multicellular organismal signaling | NRCAM; ATP2B1; ATP2B3; PAFAH1B1 a; | 472 | 9 | 2.38 | 5.74 × 10–3 | 3.36 × 10–2 | |
| Regulation of anatomical structure size | ARPC2 b; ARPC1A b; RAB21 a; MAP1B; NRCAM; PAFAH1B1 a; | 472 | 9 | 2.36 | 5.74 × 10–4 | 3.36 × 10–2 | |
| Cytosolic transport | VPS26B; DCTN1; RAB21 a; SNX5 b; | 138 | 5 | 0.69 | 6.46 × 10–4 | 3.51 v 10–2 | |
| Microtubule-basedmovement | DCTN1; RAB21 a; MAP1B; PAFAH1B1 a; | 226 | 6 | 1.14 | 9.50 × 10–4 | 4.83 × 10–2 | |
|
| Vesicle-mediated transport | ARPC2 b; DCTN2 b; ARPC1A b; RAB10; DCTN1; RAB21 a; SNX5 b; LRP1 b; ARRB1 b; PAFAH1B1 a; COPS4; SPTAN1 b; YWHAB; | 670 | 17 | 3.84 | 1.17 × 10–7 | 1.87 × 10–4 |
| Apoptosis | PLEC; DIABLO; PSMB1; SPTAN1 b; YWHAB; | 174 | 8 | 1 | 6.07 × 10–3 | 1.57 × 10–3 | |
| Rho GTPase Effectors | ARPC2 b; ARPC1A b; CLASP1; | 311 | 10 | 1.78 | 9.32 × 10–6 | 1.86 × 10–3 | |
| Signaling by Rho GTPases | ARPC2 b; ARPC1A b; CLASP1; ARHGDIA; | 446 | 11 | 2.56 | 3.82 × 10–5 | 5.10 × 10–3 | |
| Axon guidance | ARPC2 b; ARPC1A b; CLASP1; ARRB1 b; | 573 | 12 | 3.28 | 8.00 × 10–5 | 8.00 × 10–3 | |
| Cell Cycle | DCTN2 b; DCTN1; CLASP1; NUMA1 b; PAFAH1B1 a; | 635 | 11 | 3.64 | 8.40 × 10–4 | 5.60 × 10–2 | |
|
| |||||||
|
| Mitochondrial diseases | 353 | 17 | 2.32 | 1.53 × 10–10 | 4.0 × 10–7 | |
| Mental disorders | ADH5; GABRA6 b; PCLO b; ANK3 b; MARK1; MOG; ATP1A3 b; PIP4K2A b; SLC17A7; PTPRD b; SMS; SYP b; SYN3 b; PICALM b; SLC25A12 b | 679 | 15 | 4.45 | 3.83 × 10–5 | 2.01 × 10–2 | |
|
| Generation of precursor metabolites and energy | COX17; CS b; | 365 | 18 | 3.36 | 6.47 × 10–9 | 4.93 × 10–6 |
| Mitochondrial respiratory chain complex assembly | COX17; | 290 | 11 | 2.67 | 7.61 × 10–5 | 9.67 × 10–3 | |
| Nucleoside triphosphate metabolic process | 421 | 13 | 3.88 | 1.36 × 10–4 | 1.48 × 10–2 | ||
| Glycosyl compound | 34 | 4 | 3.13 | 2.59 × 10–4 | 2.45 × 10–2 | ||
| ATP hydrolysis-coupled transmembrane transport | ATP1A1 b; ATP1A3 b; ATP6V1C1; ATP6AP1 b | 37 | 4 | 0.34 | 3.59 × 10–4 | 3.04 × 10–2 | |
| Tricarboxylic acid metabolic process | CS b; | 37 | 4 | 0.34 | 3.59 × 10–5 | 3.04 × 10–3 | |
|
| The citric acid (TCA) cycle and respiratory electron transport | CS b; | 171 | 13 | 1.79 | 2.19 × 10–8 | 3.50 × 10–5 |
| Neutrophil degranulation | HUWE1; ARPC5; ACTR2; ATG7; SIRPA b; ERP44 a,b; METTL7A b; DBNL; RAB37 b; ACLY a; PRCP b; PSAP; RAP1B; | 487 | 16 | 5.07 | 4.0 × 10–5 | 1.28 × 10–2 | |
Total number: number of reference proteins in category/pathways; observed number: proteins in the data set and also in category/pathways; E: expected in the category and adjusted p-value is corrected for test multiple. Bold shows proteins from stress or mitochondrial diseases also found in other categories. a,b shows proteins previously reported in protein level analysis (a) and gene expression analyses (b) in the cerebellum (Supplementary Dataset S2).
Figure 3Network generation formed by altered pathways in cerebellum. (A) A protein–protein interaction network for up-regulated pathways. (B) A protein–protein interaction network for down-regulated pathways. The interaction overview shows how proteins overlap in the different enriched pathways (Figure 2C). Each node represents a protein. Color denotes membership to the module. The colored edge (connections between nodes) represents the type of interaction between nodes. Highlighted gene symbols represent the most robust hit protein for each module. In the mixed module, the candidate selected belonged to at least three different pathways. a indicates the proteins previously report in the proteomic studies in cerebellum; b indicates proteins previously reported in the gene expression analysis in iPSC and cerebellum. The right panels show the level of protein expression determined by immunohistochemistry for each protein in the modules and their localization in the different layers in the cerebellum.
Figure 4Analysis of hit proteins from altered pathways in a human SZ cohort and two double-hit SZ murine models. Protein levels of candidate hit proteins CLASP1 (A), YWHAZ (B), NDUFB9 (C) and METTL7A (D) from the indicated enriched pathway in SZ were analyzed in the cerebellum of the human SZ cohort (control: n = 14; SZ = 12) by proteomics, and in the two double-hit SZ murine models, maternal deprivation combined with social isolation (MD/Iso) or chronic restraint stress (MD/RS) (control: n = 11; MD/Iso model: n = 9; MD/RS model: n = 8) by immunoblot. TCA-RET: citric acid cycle-respiratory electron transport. VTM: vesicle-mediated transport. SZ, schizophrenia. LFQ, Label free quantitative. WB, Western blot. Full images of immunoblots are available in Figure S3. Statistical analysis was performed using Student’s t-test for samples with normal distribution, and the Mann–Whitney U test was carried out for non-parametric distribution in the MD/RS model for NDUFB9 and the MD/Iso and MD/RS models for CLASP1 and YWHAZ. Protein levels were normalized to the mean of the controls. Individual values represent the protein levels for each subject or animal. Means and standard deviations are shown in the graphs. ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.